Parent Hub
VerifiedSupps Articles Library
Use the main article hub to compare evidence-based guides on peptides, obesity medications, metabolic health, supplement safety, and emerging clinical research.
MariTide decision decoder
Use this quick table to separate the monthly-injection appeal from what the evidence actually supports today.
Best next step (today): treat MariTide as a Phase 3 medication candidate to monitor, not as something to buy, dose, or stack on your own.
Does MariTide work for weight loss?
MariTide appears to produce clinically meaningful weight loss in Phase 2 trials. The main caveat is that it is not approved yet, and the strongest decision-grade answer will come from larger Phase 3 studies.
Mechanism
- The GLP-1 receptor agonist part is intended to reduce appetite, improve fullness, and support glucose regulation.
- The GIP receptor antagonist part is the unusual feature; MariTide blocks GIP signaling rather than activating it like tirzepatide does.
- The antibody-peptide design gives MariTide a long-acting profile, which is why monthly or less frequent dosing is being studied.
How much weight loss did MariTide show?
In Phase 2, MariTide produced substantial 52-week weight loss in adults with obesity or overweight, both with and without type 2 diabetes. Results vary depending on whether you read the treatment-policy estimand or the efficacy estimand.
The important nuance: the efficacy estimand estimates effect under better adherence, while the treatment-policy result is usually closer to a conservative real-world decision frame.
What dose of MariTide is being studied?
There is no approved MariTide dose for routine weight-loss care. Phase 2 studied monthly fixed doses and dose-escalation schedules, while Phase 3 is using lower starting doses and structured escalation to improve gastrointestinal tolerability.
Trial doses are not self-use instructions. For long-acting injectables, starting dose, step-up schedule, missed doses, and side-effect management can materially change safety.
How often is MariTide injected?
MariTide is being studied as a monthly or less frequently dosed subcutaneous injection. That is the main feature separating it from weekly injectable obesity medications, but less frequent dosing still needs to prove long-term efficacy, tolerability, and maintenance value.
A useful way to think about it: monthly dosing may reduce treatment friction, but the medication still has to work safely through months and years, not just through the first few injections.
What side effects can MariTide cause?
The clearest MariTide side-effect pattern is gastrointestinal. Nausea, vomiting, retching, diarrhea, constipation, and abdominal symptoms are the main issues to understand, especially around the initial dosing period.
No new safety signals were reported in the Phase 2 obesity study, but that does not remove the need for larger Phase 3 safety data, careful screening, and clinician-supervised use if the medication is ever approved.
MariTide troubleshooting: what if results or side effects do not make sense?
Because MariTide is investigational, troubleshooting should not mean changing dose, route, or source on your own. The safer frame is to protect the evidence signal, track objective trends, and use a clinician or trial team to interpret symptoms.
Common mistakes
- Assuming monthly dosing means fewer side effects for everyone.
- Comparing MariTide with Wegovy, Zepbound, or investigational drugs without matching trial duration, population, dose, and estimand.
- Ignoring muscle-preserving basics during appetite suppression: protein, resistance training, sleep, hydration, and enough nutrient-dense food.
Clean test protocol
How to tell it’s working
A useful response is not only a lower scale number. Better signals include steadier appetite, gradual waist reduction, manageable side effects, preserved strength where possible, better glucose or blood-pressure markers when tracked, and the ability to keep nutrition quality intact.
Red flags / seek care
Seek care for persistent vomiting, severe or persistent abdominal pain, signs of dehydration, fainting, chest pain, yellowing skin or eyes, severe allergic symptoms, confusion, severe weakness, severe low-blood-sugar symptoms, or thoughts of self-harm.
Is MariTide approved or still in trials?
MariTide is still investigational and is not approved for routine clinical use. The MARITIME Phase 3 program is evaluating chronic weight management in adults with obesity or overweight, including studies with and without type 2 diabetes.
The program has also expanded into obesity-related conditions, including cardiovascular outcomes, heart failure, obstructive sleep apnea, switch studies from weekly therapies, long-term extensions, type 2 diabetes studies, and a liver-fat study.
Decision rule
A large Phase 3 program is a strong development signal, but it is not an approval. Wait for Phase 3 results, regulatory review, final label, contraindications, and real-world access rules.
How does MariTide compare with Wegovy or Zepbound?
MariTide is not just a longer-acting version of existing GLP-1 medications. It activates GLP-1 signaling and blocks GIP receptor signaling, while Wegovy uses semaglutide as a GLP-1 receptor agonist and Zepbound uses tirzepatide as a GIP/GLP-1 receptor agonist.
The calm comparison is this: MariTide may become attractive if monthly dosing, durable maintenance, and tolerability hold up in Phase 3. Until then, approved weekly options remain the practical clinical pathway in markets where they are available.
Go Deeper (VerifiedSupps Guides)
Use these related guides to compare MariTide with nearby next-generation obesity medications without mixing up mechanisms, trial stages, and approved use.
Mazdutide for Weight Loss
Compare a GLP-1/glucagon dual agonist with MariTide’s GLP-1 plus GIP-blocking strategy.
Pemvidutide for Weight Loss and Fatty Liver
A liver-focused dual agonist guide for readers comparing metabolic-health and obesity outcomes.
Retatrutide: Weight Loss, Side Effects, and Status
Compare MariTide with a triple-agonist research path while keeping approval status clear.
CagriSema for Weight Loss
Understand a different combination strategy: GLP-1 plus amylin rather than GLP-1 plus GIP antagonism.
Final Takeaway
MariTide is a serious monthly weight-loss medication candidate with strong Phase 2 data and a distinctive GLP-1 plus GIP-blocking mechanism. The best decision today is to watch the Phase 3 MARITIME program and avoid unregulated access while using approved, clinician-guided options for actual treatment decisions.
FAQ
What is MariTide?
MariTide is the brand-style development name for maridebart cafraglutide, also known as AMG 133. It is an investigational long-acting antibody-peptide conjugate that activates GLP-1 signaling and antagonizes the GIP receptor.
Is MariTide approved for weight loss?
No. MariTide is still investigational and is not approved for routine weight-loss treatment. It is being studied in the MARITIME Phase 3 program.
How much weight loss did MariTide show?
In Phase 2, adults without type 2 diabetes lost 12.3% to 16.2% by the treatment-policy estimand and 16.3% to 19.9% by the efficacy estimand at 52 weeks. Adults with type 2 diabetes lost 8.4% to 12.3% by treatment-policy analysis and 12.1% to 17.0% by efficacy-estimand analysis.
Is MariTide a monthly injection?
Yes, monthly dosing is the central development concept, and less frequent maintenance schedules are also being studied. That does not mean there is an approved consumer dosing schedule yet.
What are the main MariTide side effects?
The main side effects reported in Phase 2 were gastrointestinal, including nausea, vomiting, retching, diarrhea, constipation, and abdominal symptoms. Dose escalation appears important for tolerability.
How is MariTide different from tirzepatide?
Tirzepatide activates GIP and GLP-1 receptors. MariTide activates GLP-1 signaling but antagonizes the GIP receptor, which is a different biological strategy.
What dose of MariTide was studied?
Phase 2 studied monthly fixed doses including 140 mg, 280 mg, and 420 mg, plus less frequent and dose-escalation strategies. Phase 3 uses lower starting doses and structured escalation. These are study doses, not self-use instructions.
Does MariTide help people with type 2 diabetes?
Phase 2 data showed meaningful weight loss and HbA1c improvement in adults with obesity and type 2 diabetes. Dedicated type 2 diabetes Phase 3 studies are part of the broader development plan.
Can MariTide be taken every three months?
Quarterly dosing is being explored mainly in maintenance and extension settings. It is not an approved starting schedule or routine treatment plan.
Can you buy MariTide online?
There is no approved MariTide product for routine use. Online research-vial listings are not the same as regulated clinical medication and should not be treated as a safe substitute.
VerifiedSupps Medical Disclaimer
MariTide is an investigational medication, not a dietary supplement or approved weight-loss treatment. This article is for educational purposes only and does not provide medical advice, diagnosis, prescribing guidance, dosing instructions, injection instructions, or a recommendation to purchase unapproved products. Obesity medications can cause meaningful side effects and may be unsafe with certain medical conditions or medications, especially diabetes medications, pregnancy considerations, gallbladder disease, pancreatitis history, kidney disease, liver disease, severe gastrointestinal symptoms, complex cardiovascular risk, or sleep apnea. Speak with a licensed clinician before considering any obesity medication, and seek urgent care for severe abdominal pain, persistent vomiting, dehydration, fainting, chest pain, jaundice, severe allergic symptoms, severe low-blood-sugar symptoms, confusion, or thoughts of self-harm.
